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Dietary casein promotes a progressive decline in the
glomerular filtration rate (GFR) of remnant kidneys associated
with metabolic acidosis and an endothelin-mediated increase
in renal acidification. We tested whether diets that affect the
acid–base status contributes to the decline of GFR through
endothelin receptors in rats with a remnant kidney. Rats on a
casein diet had metabolic acidosis at baseline and developed
a progressive decline in GFR after renal mass reduction.
Dietary sodium bicarbonate but not sodium chloride
ameliorated metabolic acidosis and prevented the decrease
in GFR but only after the sodium bicarbonate-induced
increase in blood pressure was treated. Dietary soy protein
did not induce baseline metabolic acidosis and rats with
remnant kidney on a soy diet had no decrease in their GFR.
By contrast, rats with a remnant kidney on soy protein given
dietary acid developed metabolic acidosis and a decreased
GFR. This decline in GFR was prevented in either case by
endothelin A but not endothelin A/B receptor antagonism.
Our study suggests that the casein-induced decline in GFR of
the remnant kidney is mediated by metabolic acidosis
through endothelin A receptors.
Kidney International (2008) 73, 192–199; doi:10.1038/sj.ki.5002647;
published online 31 October 2007
KEYWORDS: acid; albuminuria; alkali; blood pressure; bosentan; darusentan;
nephrectomy
Increased dietary intake of protein as casein induces kidney
injury in rats with intact nephron mass mediated by increased
intrinsic acid production through endothelin A receptors.1
Nevertheless, glomerular filtration rate (GFR) was preserved
after nearly 2 years of follow-up.1 By contrast, increased intake
of dietary casein in rats with reduced nephron mass induces
kidney injury as well as reduces GFR,2 each of which is
ameliorated by reduced dietary casein intake.3 Dietary casein
increases intrinsic acid production4 and high-protein diet as
casein induces endothelin-mediated kidney acidification that
facilitates acid excretion.5–7 Endothelin has been implicated as a
mediator of glomerulosclerosis8 and tubulo-interstitial injury,1,9
and so might contribute to kidney injury associated with dietary
casein. On the other hand, dietary protein as soy induces less
intrinsic acid production than casein4 and is associated with less
injury in remnant kidneys.10 Animals with reduced nephron
mass might be more susceptible to casein-induced kidney
injury, because this acid load is more likely associated with
chronic metabolic acidosis in these animals11 than in those with
intact nephron mass.12 Male Munich–Wistar rats are at higher
risk for kidney injury than other strains,13 and it was in this
strain that dietary protein-induced, endothelin-mediated aug-
mented kidney acidification was shown.5–7 This study tested the
hypothesis that dietary casein induces kidney injury measured
by increased urine albumin excretion (UalbV) and reduces GFR
in remnant kidneys mediated by increased intrinsic acid
production through endothelin receptors.
RESULTS
Systolic Blood Pressure of conscious rats
Table 1 shows that Casein-eating Nx (Casein Nx) had higher
tail–cuff systolic blood pressure (SBP) at 12 weeks than Casein
sham. Casein Nx eating additional NaHCO3 or NaCl had
higher SBP than Casein Nx not receiving either salt. Table 1
also shows that SBP in Casein NxþNaHCO3 and Casein
NxþNaCl receiving the oral antihypertensive cocktail
(methyl dopaþ hydralazineþ hydrochlorothiazide) was com-
parable to Casein Nx at 12 weeks. SBP was lower in Casein Nx
eating additional CaHCO3 than NaHCO3 as shown in Table 1.
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By contrast, Table 1 shows that SBP was similar in Casein Nx
eating CaHCO3 or NaHCO3 when SBP in the latter was
reduced with the antihypertensive cocktail. SBP was higher in
Soy Nx than in Soy sham, but was similar in Casein Nx eating
CaHCO3 or Ca Gluconate (CaGlu) and was similar among
the remaining group comparisons in Table 1.
Plasma TCO2 of conscious rats
Table 2 shows lower plasma total CO2 (PTCO2) at 12 weeks
in Casein Nx compared to Casein sham. Because arterial
PCO2 (37.8±0.7 vs 40.2±0.8 mm Hg, Po 0.04) and pH
(7.391±0.007 vs 7.417±0.008, Po 0.03) were also lower in
Casein Nx than in Casein sham, Casein Nx animals had
metabolic acidosis. Casein Nx eating NaHCO3, but not NaCl,
had higher PTCO2 without and with reduced SBP. Although
PTCO2 was similar in Casein Nx eating NaHCO3 or
CaHCO3, PTCO2 was higher in Casein Nx eating CaHCO3
than CaGlu. PTCO2 was similar in Soy Nx and Soy sham,
unlike the Casein Nx compared to Casein sham. Nevertheless,
PTCO2 was lower in Soy Nx eating NH4SO4, but not NaSO4,
than in Soy Nx not eating either salt. Because arterial PCO2
(36.2±0.6 vs 40.9±0.7 mm Hg, Po0.001) and pH
(7.377±0.009 vs 7.420±0.008, Po0.004) were also lower
in Soy NxþNH4SO4 than in Soy Nx, Soy NxþNH4SO4 had
metabolic acidosis. PTCO2 was similar in the remaining
Table 2 groups.
Urine net acid excretion of conscious rats
Table 3 shows that urine net acid excretion (NAE) and urine
ammonium excretion (UNH4þV) at 12 weeks were not
different in Casein sham and Casein Nx, but TCO2 excretion
and pH were lower in Casein Nx. Casein Nx eating NaHCO3,
but not NaCl, had lower urine NAE than Casein Nx not
eating either salt. This pattern was qualitatively the same for
comparisons among Casein Nx eating NaHCO3 or NaCl in
animals with pharmacologically reduced SBP. NAE was
similar in Casein Nx eating CaHCO3 or NaHCO3, but NAE
was lower in Casein Nx eating CaHCO3 than CaGlu. NAE
was similar in Soy Nx and Soy sham. By contrast, Soy Nx
eating NH4SO4, but not NaSO4, had higher urine NAE than
Soy Nx not eating additional salts. NAE was not different in
bosentan- or darusentan-ingesting Casein Nx or Soy
NxþNH4SO4.
Urine endothelin-1 excretion of conscious rats
Casein Nx had higher urine endothelin-1 (ET-1) excretion
(UET-1V) than Casein sham, as shown in Table 4. Addition-
ally, Table 4 shows similar UET-1V among Casein Nx eating
NaHCO3 or NaCl and those not eating additional salts. By
contrast, Casein Nx eating NaHCO3 had lower UET-1V than
Casein Nx eating NaCl and Casein Nx not eating either salt
when SBP was reduced with the antihypertensive cocktail.
Casein Nx eating CaHCO3 had lower UET-1V than Casein Nx
eating NaHCO3 without SBP reduction. By contrast, UET-1V
in Casein Nx eating NaHCO3 with reduced SBP was similar
to Casein Nx eating CaHCO3. Casein Nx eating CaHCO3 had
lower UET-1V than Casein Nx eating CaGlu. UET-1V was
higher in Soy Nx than in Soy sham. In addition, UET-1V was
higher in Soy Nx eating NH4SO4 than Soy Nx eating NaSO4
and Soy Nx not eating either salt.
UalbV and GFR course in Nx vs sham
UalbV was higher in Casein Nx than in Casein sham at both 1
and 12 weeks and increased between these time points as
shown in Table 5. By contrast, GFR was lower in Casein Nx
than in Casein sham and decreased between these time points
in Casein Nx but not in Casein sham as shown in Table 6.
Urine phosphorous excretion was similar between Casein Nx
Table 1 | Tail–cuff SBP in conscious animals in mm Hg (n=8 animals for all groups)
Casein sham Casein Nx P-value
98±2 112±4a 0.008
Casein Nx Casein Nx+NaCl Casein Nx+NaHCO3
111±5 166±8a 159±8a o0.001
Casein Nx Casein Nx+NaCl (reduced SBP) Casein Nx+NaHCO3 (reduced SBP)
114±5 120±5 119±5 0.55
Casein Nx+NaHCO3 Casein Nx+CaHCO3 —
155±8 117±6a — 0.002
Casein Nx+NaHCO3 (reduced SBP) Casein Nx+CaHCO3 —
116±5 112±4 — 0.54
Casein Nx+CaGluc Casein Nx+CaHCO3 —
120±9 115±7 — 0.747
Soy sham Soy Nx
95±3 105±3a 0.034
Soy Nx Soy Nx+NaSO4 Soy Nx+NH4SO4
107±4 118±6 109±6 0.431
Casein Nx Casein Nx+bosentan Casein Nx+darusentan
116±6 108±5 104±5 0.223
Soy Nx+NH4SO4 Soy Nx+NH4SO4+bosentan Soy Nx+NH4SO4+darusentan
110±5 107±5 105±6 0.778
CaGlu, Ca Gluconate; SBP, systolic blood pressure.
aDifference from respective value in column #1.
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and Casein sham (1.4±0.2 vs 1.7±0.2 mg day1, respec-
tively, P¼ 0.31). Regarding soy-eating animals, Table 5 shows
that UalbV was similar in Soy Nx and Soy sham at 12 weeks,
although each value increased between 1 and 12 weeks in
both Soy groups. As with Casein Nx, urine phosphorous
excretion was similar between Soy Nx and Soy sham
(1.1±0.2 vs 1.3±0.2 mg day1, respectively, P¼ 0.49). In
contrast to Casein Nx, Table 6 shows that GFR was not
different between 1 and 12 weeks in either Soy sham or Soy
Nx. Because Casein Nx, but not Soy Nx, had metabolic
acidosis and because each Nx had higher SBP compared to
respective shams, subsequent experiments tested the hypo-
thesis that casein-induced metabolic acidosis mediated the
GFR decline observed in Casein Nx between 1 and 12 weeks.
Table 2 | Arterial plasma TCO2 in conscious animals in mM (n=8 animals for all groups)
Casein sham Casein Nx P-value
24.8±0.7 22.4±0.6a 0.021
Casein Nx Casein Nx+NaCl Casein Nx+NaHCO3
22.3±0.6 21.6±0.6 25.2±0.7a 0.022
Casein Nx Casein Nx+NaCl (reduced SBP) Casein Nx+NaHCO3 (reduced SBP)
22.2±0.6 21.4±0.7 25.0±0.7a 0.027
Casein Nx+NaHCO3 Casein Nx+CaHCO3 —
25.3±0.7 24.9±0.7 — 0.692
Casein Nx+NaHCO3 (reduced SBP) Casein Nx+CaHCO3 —
25.1±0.7 25.0±0.6 — 0.92
Casein Nx+CaGluc Casein Nx+CaHCO3 —
22.8±0.7 25.1±0.7a — 0.036
Soy sham Soy Nx
26.0±0.6 25.8±0.6 0.817
Soy Nx Soy Nx+NaSO4 Soy Nx+NH4SO4
25.7±0.6 25.0±0.6 20.7±0.6a 0.0005
Casein Nx Casein Nx+bosentan Casein Nx+darusentan
22.5±0.6 22.0±0.6 22.7±0.7 0.477
Soy Nx+NH4SO4 Soy Nx+NH4SO4+bosentan Soy Nx+NH4SO4+darusentan
20.2±0.6 20.0±0.5 20.5±0.5 0.506
CaGlu, Ca Gluconate; SBP, systolic blood pressure; TCO2, total CO2.
aDifference compared to respective value in column #1.
Table 3 | NAE and its components in conscious animals in lmol day1 (n=8 animals for all groups)
Group NAE NH4
+ excretion TA excretion TCO2 excretion Urine pH
Casein sham 3710±501 2019±218 1760±182 69±9 6.86±0.02
Casein Nx 2694±381 1545±185 1152±109 3±1a 6.12±0.02a
Casein Nx 2788±371 1589±169 1201±371 2±1 6.16±0.02
Casein Nx+NaCl 2452±296 1324±140 1169±122 42±6a 6.43±0.02a
Casein Nx+NaHCO3 1498±186
a 847±94a 687±82a 35±5a 6.39±0.03a
Casein Nx 2871±343 1639±177 1236±129 4±2 6.18±0.02
Casein Nx+NaCl (reduced SBP) 2261±265 1171±122 1114±120 25±4 6.33±0.02a
Casein Nx+NaHCO3 (reduced SBP) 1264±169
a 725±78a 559±64a 20±4a 6.28±0.02a
Casein Nx+NaHCO3 1320±177 758±86 590±71 29±5 6.31±0.02
Casein Nx+CaHCO3 1572±215 877±95 719±82 24±4 6.27±0.03
Casein Nx+NaHCO3 (reduced SBP) 1652±184 943±101 749±86 40±6 6.33±0.02
Casein Nx+CaHCO3 1497±215 855±98 673±79 31±4 6.28±0.02
Casein Nx+CaGluc 2644±318 1535±163 1110±115 2±1 6.15±0.02
Casein Nx+CaHCO3 1501±208
a 861±92a 677±74a 37±5a 6.34±0.02a
Soy sham 1810±296 990±152 918±139 99±11 6.99±0.02
Soy Nx 1689±243 935±118 777±104 33±4a 6.36±0.02a
Soy Nx 1721±225 891±92 875±89 45±5 6.43±0.02
Soy Nx+NaSO4 1986±264 1048±121 957±102 19±3
a 6.36±0.03
Soy Nx+NH4SO4 4092±497
a 2248±230a 1853±209a 9±2a 6.21±0.02a
Casein Nx 2655±454 1524±168 1135±124 5±2 6.15±0.03
Casein Nx+bosentan 2485±459 1295±133 1197±131 7±3 6.20±0.04
Casein Nx+darusentan 2614±429 1511±130 1107±119 4±2 6.14±0.03
Soy Nx+NH4SO4 3746±511 2130±289 1622±186 5±3 6.20±0.03
Soy Nx+NH4SO4+bosentan 3882±569 2016±256 1875±223 10±4 6.24±0.04
Soy Nx+NH4SO4 +darusentan 4012±610 2121±239 1895±241 4±2 6.19±0.04
CaGlu, Ca Gluconate; NAE, net acid excretion; SBP, systolic blood pressure; TA, titratable acid excretion; TCO2, total CO2.
aDifference compared to first group in each set of comparisons.
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Aim 1: relate detrimental effects of casein on GFR in Casein
Nx to casein-induced metabolic acidosis
Casein Nx eating NaHCO3, but not NaCl, had higher PTCO2
than Casein Nx (Table 2), indicating amelioration of the
metabolic acidosis in Casein Nx. Table 5 shows that Casein
Nx eating NaCl, but not NaHCO3, had higher UalbV than
Casein Nx. Table 6 shows that Casein Nx eating NaCl, but
not NaHCO3, had lower GFR than Casein Nx. Although
added dietary NaHCO3 improved metabolic acidosis in
Casein Nx, its addition did not lead to the hypothesized
reduced UalbV or increased GFR. Because added NaHCO3
(and NaCl) increased SBP (Table 1), we explored if increased
SBP abrogated the hypothesized decreased UalbV and
increased GFR.
Aim 2: compare supplemental NaHCO3 and NaCl effects when
SBP was pharmacologically reduced to a level comparable to
sham
Table 2 shows that the antihypertensive cocktail reduced SBP
in Casein NxþNaHCO3 and Casein NxþNaCl comparable
to Casein Nx. Table 5 shows that in the context of reduced
SBP, UalbV at 12 weeks was lower in Casein NxþNaHCO3
than in Casein Nx and Casein NxþNaCl. Furthermore,
Table 6 shows that when SBP was reduced, GFR at 12 weeks
Table 4 | Urine endothelin excretion in conscious animals in fmol day1 (n=8 animals for all groups)
Casein sham Casein Nx P-value
78±13 315±52 o0.001
Casein Nx Casein Nx+NaCl Casein Nx+NaHCO3
393±58 315±41 244±28 0.51
Casein Nx Casein Nx+NaCl (reduced SBP) Casein Nx+NaHCO3 (reduced SBP)
411±53 316±40 142±18a 0.005
Casein Nx+NaHCO3 Casein Nx+CaHCO3 —
266±29 132±33a — 0.009
Casein Nx+NaHCO3 (reduced SBP) Casein Nx+CaHCO3 —
131±17 122±30 — 0.80
Casein Nx+CaGluc Casein Nx+CaHCO3 —
355±58 151±20a — 0.005
Soy sham Soy Nx
75±10 148±22a 0.009
Soy Nx Soy Nx+NaSO4 Soy Nx+NH4SO4
137±15 79±10 219±23a 0.029
CaGlu, Ca Gluconate; SBP, systolic blood pressure.
aDifference from respective value in column #1.
Table 5 | UalbV in conscious animals in mg/day (n=8 animals for all groups)
Group 1 week 12 weeks P-value (12 weeks vs 1 week) P-value (vs index at 12 weeks)
Casein sham 7±1 12±2a 0.019 —
Casein Nx 29±6b 158±18b o0.001 o0.001
Casein Nx 37±4 166±18a o0.001 —
Casein Nx+NaCl 36±5 256±26a,b o0.001 0.039
Casein Nx+NaHCO3 41±5 211±23
a o0.001 0.417
Casein Nx 34±4 151±17a o0.001 —
Casein Nx+NaCl (reduced SBP) 38±5 179±19a o0.001 0.668
Casein Nx+NaHCO3 (reduced SBP) 35±5 92±10
a,b 0.004 0.029
Casein Nx+NaHCO3 38±5 220±24
a o0.001 —
Casein Nx+CaHCO3 38±4 109±11
a,b 0.008 0.0009
Casein Nx+NaHCO3 (reduced SBP) 35±5 133±15
a 0.001 —
Casein Nx+CaHCO3 32±5 115±13
a 0.002 0.589
Casein Nx+CaGluc 30±4 149±15a o0.001 —
Casein Nx+CaHCO3 33±4 102±10
a,b 0.003 0.021
Soy sham 5±1 29±3a 0.019 —
Soy Nx 7±2 36±4a o0.001 o0.001
Soy Nx 8±1 32±4a 0.017 —
Soy Nx+NaSO4 7±2 30±4
a 0.022 0.853
Soy Nx+NH4SO4 7±2 68±7
a,b o0.001 0.003
Casein Nx 37±4 170±19a o0.001 —
Casein Nx+bosentan 41±5 152±16a o0.001 0.772
Casein Nx+darusentan 31±5 110±10a,b o0.001 0.043
Soy Nx+NH4SO4 8±2 68±8
a o0.001 —
Soy Nx+NH4SO4+bosentan 7±2 64±7
a o0.001 0.875
Soy Nx+NH4SO4+darusentan 8±2 39±5
a,b 0.009 0.035
CaGlu, Ca Gluconate; SBP, systolic blood pressure; UalbV, urine albumin excretion.
aSignificance comparing the 12 weeks to the respective 1 week value.
bSignificance when compared to the first group (index value) in each set of comparisons.
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was higher in Casein NxþNaHCO3 than in Casein Nx and
Casein NxþNaCl. These data support the hypothesis, but
Casein NxþNaHCO3 animals had both reduced SBP and
improved metabolic acidosis. Subsequent experiments
attempted to separate effects of these phenomena.
Aim 3: compare effects of added dietary salts that each
ameliorated metabolic acidosis but only one increased SBP
Table 1 shows that adding dietary NaHCO3 and CaHCO3 to
Casein Nx yielded PTCO2 comparable to sham and not
different from each other. By contrast, Table 1 shows that
these dietary additions led to higher SBP in Casein
NxþNaHCO3 than Casein NxþCaHCO3. Table 5 shows
that UalbV at 12 weeks was lower in Casein NxþCaHCO3
than Casein NxþNaHCO3. Furthermore, Table 6 shows that
although GFR at 12 weeks was similar in the two groups, GFR
decreased between 1 and 12 weeks in Casein NxþNaHCO3,
but not in Casein NxþCaHCO3, consistent with better GFR
preservation in the latter group. As expected, urine calcium
excretion was higher in Casein NxþCaHCO3 than in Casein
NxþNaHCO3 (4.4±0.5 vs 2.1±0.2 mg day1, respectively,
Po 0.001). The data suggest an ameliorating effect of
NaHCO3, but subsequent experiments attempted to rule out
the effects of increased SBP.
Aim 4: compare effects of added dietary CaHCO3 and NaHCO3
with SBP of the latter pharmacologically reduced
Table 1 shows similar SBP in Casein NxþNaHCO3 getting the
antihypertensive cocktail and Casein NxþCaHCO3. Table 5
shows that UalbV at 12 weeks was similar in Casein Nxþ
CaHCO3 and Casein NxþNaHCO3 (latter with pharmacologic
SBP reduction). Table 6 shows similar GFR at 12 weeks in
Casein NxþCaHCO3 and Casein NxþNaHCO3 (latter with
SBP reduction), and there was no GFR decrease between 1 and
12 weeks in either group, consistent with GFR preservation.
These data support the stated hypothesis, but subsequent
experiments attempted to rule out possible salutary effects of
the antihypertensive medications independent of reduced SBP.
Aim 5: rule out possible salutary effects of the antihyper-
tensive cocktail independent of its effects to reduce SBP
Table 1 shows Casein NxþCaHCO3 and Casein NxþCaGlu
with comparable SBP, and their SBP are each lower than
Casein Nx. By contrast, Table 2 shows that Casein
NxþCaHCO3, but not Casein NxþCaGlu, ameliorated
the metabolic acidosis of Casein Nx. Table 5 shows that UalbV
at 12 weeks was lower in Casein NxþCaHCO3 than in
Casein NxþCaGlu. Table 6 shows that GFR at 12 weeks was
higher in Casein NxþCaHCO3 than in Casein NxþCaGlu.
In addition, Table 6 shows that GFR decreased between 1 and
12 weeks in Casein NxþCaGlu, but not in Casein
NxþCaHCO3, supporting better GFR preservation in the
latter. In contrast with the earlier studies in which Ca2þ and
non-Ca2þ salts were compared, urine Ca2þ excretion was
similar in Casein NxþCaHCO3 and Casein NxþNaHCO3
(4.2±0.5 vs 3.4±0.3 mg day1, respectively, P¼ 0.19). These
data support that metabolic acidosis in Casein Nx contributes
to the GFR reduction that occurs between 1 and 12 weeks.
Table 6 | GFR in conscious animals in ll min1 (n=8 animals for all groups)
Group 1 week 12 weeks
P-value
(12 weeks vs 1 week)
P-value
(vs index at 12 weeks)
Casein sham 3384±278 3512±288 0.42 —
Casein Nx 1210±94a 808±61b,a o0.001 o0.0001
Casein Nx 1222±98 813±68b o0.001 —
Casein Nx+NaCl 1182±90 587±48b,a o0.001 0.049
Casein Nx+NaHCO3 1178±91 952±74
b 0.037 0.565
Casein Nx 1195±89 818±60b 0.005 —
Casein Nx+NaCl (reduced SBP) 1171±88 762±75b o0.001 0.765
Casein Nx+NaHCO3 (reduced SBP) 1201±87 1189±81
a 0.469 0.008
Casein Nx+NaHCO3 1191±85 908±71
b 0.012 —
Casein Nx+CaHCO3 1180±83 1110±88 0.298 0.096
Casein Nx+NaHCO3 (reduced SBP) 1251±90 1192±97 0.351 —
Casein Nx+CaHCO3 1222±92 1149±95 0.364 0.756
Casein Nx+CaGluc 1198±94 839±66b 0.004 —
Casein Nx+CaHCO3 1225±99 1141±87
a 0.271 0.015
Soy sham 2378±185 2456±199 0.778 —
Soy Nx 937±81a 859±80a 0.241 o0.0001
Soy Nx 844±68 806±61 0.312 —
Soy Nx+NaSO4 911±72 839±77 0.223 0.845
Soy Nx+NH4SO4 920±75 679±53
b 0.02 0.315
Casein Nx 1158±91 845±72b 0.009 —
Casein Nx+bosentan 1174±95 877±79b 0.016 0.894
Casein Nx+darusentan 1215±96 1119±85 0.249 0.081
Soy Nx+NH4SO4 925±73 632±49
b 0.003 —
Soy Nx+NH4SO4+bosentan 887±70 705±70
b 0.031 0.707
Soy Nx+NH4SO4 +darusentan 872±71 821±66 0.343 0.102
CaGlu, Ca Gluconate; GFR, glomerular filtration rate; SBP, systolic blood pressure.
aSignificance vs respective index group in each comparison set.
bSignificance vs respective 1 week value.
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Aim 6: determine if induced metabolic acidosis in Nx without
baseline metabolic acidosis leads to less GFR preservation
and/or worsens UalbV
Table 2 shows that Soy Nx and Soy sham had similar PTCO2
but adding dietary NH4SO4 to Soy Nx reduced PTCO2,
consistent with metabolic acidosis. Table 1 shows that Soy
Nx, Soy NxþNaSO4, and Soy NxþNH4SO4 had similar
SBP. Table 5 shows that Soy NxþNH4SO4 had higher UalbV
at 12 weeks than Soy NxþNaSO4 and Soy Nx. Table 6 shows
that GFR decreased between 1 and 12 weeks in Soy Nxþ
NH4SO4, but not in Soy NxþNaSO4 or Soy Nx, consistent
with less GFR preservation in Soy NxþNH4SO4, especially
considering that GFR of Soy Nx did not decrease between
these time points. GFR at 12 weeks was not different among
groups. These data support that inducing metabolic acidosis
in Nx without baseline metabolic acidosis leads to less GFR
preservation.
Aim 7: determine if effects of metabolic acidosis induced by
casein were mediated through endothelin A and/or B
receptors
Table 5 shows lower UalbV at 12 weeks in Casein
Nxþ darusentan than in Casein Nxþ bosentan and Casein
Nx. Furthermore, Table 6 shows that GFR did not decrease
between 1 and 12 weeks in Casein Nxþ darusentan animals
but did so in Casein Nxþ bosentan and Casein Nx. Similarly,
Table 5 shows lower UalbV at 12 weeks in Soy Nxþ
NH4SO4þ darusentan than in Soy NxþNH4SO4þ bosentan
and Soy NxþNH4SO4. Furthermore, Table 6 shows that GFR
did not decrease between 1 and 12 weeks in the Soy Nxþ
NH4SO4þ darusentan animals but did so in Soy Nxþ
NH4SO4þ bosentan and Soy NxþNH4SO4. These data
support that endothelin A receptor antagonism with
darusentan but not endothelin A/B antagonism with
bosentan mediates the deleterious effects of metabolic
acidosis on GFR decline in Nx.
DISCUSSION
This study tested the hypothesis that kidney injury (measured
by increased UalbV) and GFR decline in remnant kidneys
(Nx) induced by dietary casein is mediated by metabolic
acidosis through endothelin receptors. These data show that
Casein Nx compared to Casein sham has underlying
metabolic acidosis. Unlike Casein sham, Casein Nx experi-
enced a progressive GFR decline and, compared to Casein
sham, has a greater UalbV increase over the 12-week protocol.
GFR was better preserved and the UalbV increase was less in
Casein Nx when metabolic acidosis was ameliorated and the
SBP increase induced by dietary NaHCO3 was avoided. The
data also show that contrary to Casein Nx, Soy Nx and Soy
sham have similar plasma acid–base status. Soy Nx did not
experience progressive GFR decline and had less UalbV
increase after 12 weeks compared to Casein Nx. Nevertheless,
Soy Nx fed dietary acid developed metabolic acidosis with
progressive GFR decline and a greater increase in UalbV. The
acid-induced GFR decline and UalbV increase in Casein Nx
and Soy Nx ingesting acid were ameliorated by endothelin A,
but not by A/B receptor antagonists. Together, these data
support that metabolic acidosis and/or increased intrinsic
acid production in Nx contributes to kidney injury measured
by increased UalbV with progressive GFR decline, and that
these effects are mediated through endothelin A receptors.
Reduced nephron mass of Nx reduces capacity to excrete
an acid load11 and contributes to the metabolic acidosis of
Casein Nx compared to Casein sham. Interestingly, Soy Nx
compared to the Soy sham had no metabolic acidosis.
Dietary casein increases intrinsic acid production but soy
does not,4 related in part to its higher methionine content.
Consequently, dietary casein provides a greater acid challenge
than soy. Casein Nx appears to have less capacity than Casein
sham to excrete the acid load induced by dietary casein
without maintaining a sustained metabolic acidosis. By
contrast, the reduced nephron mass of Nx appears sufficient
to maintain comparable acid–base status in Soy Nx and Soy
sham with the lower acid challenge provided by the soy diet.
Ameliorating metabolic acidosis in Casein Nx while avoiding
increased SBP leads to better GFR preservation and
abrogation of the increase in UalbV.
Casein Nx have higher kidney endothelin production
measured by increased UET-1V,
11 a surrogate for increased
kidney endothelin production, than in Casein sham.12 These
data were confirmed in this study which additionally showed
that dietary alkali reduced urine endothelin excretion in
Casein Nx. Previous studies also showed that dietary acid
increased kidney endothelin production in animals with
intact nephron mass but did so without the animals
developing sustained metabolic acidosis.12 In this study,
dietary acid increased urine endothelin production in Soy Nx
that did develop sustained metabolic acidosis. These data
support that dietary casein increases kidney endothelin
production through increased intrinsic acid production with
or without sustained metabolic acidosis. Increased kidney
endothelins, in turn, appear to induce kidney injury through
endothelin A receptors as described in animals with intact
nephron mass.1 In contrast to animals with intact nephron
mass in which GFR was preserved up to 96 weeks, this study
supports that this mechanism contributes to progressive GFR
decline in Nx over 12 weeks. The reasons for this difference
were not apparent, but the ability of animals with intact
nephron mass to excrete the dietary acid challenge without
developing metabolic acidosis, in contrast to the Nx animals,
might be contributory.
Despite the importance of metabolic acidosis mediating
GFR decline in Nx, its amelioration was not kidney-protective
if the intervention concomitantly increased SBP. Preventing
increased SBP with the intervention used to ameliorate
metabolic acidosis, or ameliorating metabolic acidosis with an
intervention that did not concomitantly increase SBP, was
kidney-protective. Both interventions (ameliorated metabolic
acidosis without increased SBP) were necessary to reduce
UET-1V in Nx. Previous studies support the importance
of avoiding chronically elevated SBP in ameliorating
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the progressive kidney injury associated with Nx, even using
regimens that do not include angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers.14
In summary, dietary casein in Nx, a model of chronic
kidney disease, contributes to progressive GFR decline and
progressive kidney injury as measured by increasing UalbV.
This casein-induced injury is mediated by metabolic acidosis
through endothelin A receptors.
MATERIALS AND METHODS
Animals, protocol, and diet
The protocol for these animal studies was approved by our local
Institutional Review Board. Male Munich–Wistar rats (Harlan
Sprague–Dawley, Houston, TX, USA; approximately 8 weeks old)
ate standard rat chow (Prolab RMH 2500 with 23% protein of
various sources; Purina Labs, St Louis, MO, USA) for at least 1 week
before surgical kidney mass reduction (Nx) by removal of
approximately 5/6 of kidney mass in two stages.11 Shams had
kidney surgical exposure and manipulation but no mass reduction.
A chronic carotid arterial catheter was placed for blood sampling.
Following kidney mass reduction or sham procedure, Nx and sham
were changed to a minimum electrolyte diet (MED) with 20%
protein as purified high nitrogen casein or as soy without
isoflavones (ICN Nutritional Biochemicals, Cleveland, OH, USA)
and drank distilled H2O ad libitum. Casein and soy diets were
isocaloric (balanced with carbohydrate), but had different amino-
acid contents including higher methionine in casein (0.76 vs 0.23%).
Each contained 0.1% phosphorous. Despite casein and soy diets
having identical percent protein, the casein diet yielded greater
nitrogen excretion as shown previously.1 For these reasons,
important comparisons were made within casein and soy groups,
whereas limited comparisons were made within casein and soy. In
preliminary studies, 20% casein animals undergoing this protocol
survived at least 12 weeks following nephron mass reduction and
had higher glomerular and tubulo-interstitial indices than shams
eating this diet. Consequently, animals were studied after 12 weeks
of experimental diet.
Animals and diet protocol
The first aim was to relate the hypothesized effects of casein diet to
increased intrinsic acid production by comparing effects of
supplemental dietary salts that did and did not reduce intrinsic
acid production. Supplemental dietary NaHCO3, but not NaCl,
reduces intrinsic acid production in animals eating dietary casein.15
Naþ /Cl content of standard and MED diet was 174/200 and
22/14mM g1, respectively. To avoid a Naþ load that was much
greater than the standard diet, 150mM g1 NaHCO3 or 150 mM g
1
NaCl was added to MED for experimental and control group.
Preliminary studies showed that Nx ate slightly less casein diet than
similar weight non-Nx (17.8±0.9 vs 20.4±0.8 g day1, n¼ 4,
P¼ 0.07). Therefore, casein animals received 17 g of diet daily to
assure similar intake. Preliminary studies also showed that Nx ate
slightly less soy diet than non-Nx (15.9±0.8 vs 18.0±0.9 g day1,
n¼ 4, P¼ 0.13) and so soy animals received 15 g of diet daily.
Because increased SBP complicated interpretation of the
supplemental Naþ salt studies, the second aim was to compare
effects of supplemental salts in Nx with SBP comparable to Nx not
eating the supplemental salts. Tail–cuff SBP was reduced in the salt-
ingesting animals to a level similar to animals not eating additional
salts with a combination of methyl dopa (50 mg l1)þ hydralazine
(200 mg l1)þ hydrochlorothiazide (50 mg l1) in drinking water
for the 12-week protocol.
The third aim was to compare effects of salts that each reduced
intrinsic acid production, but only one and not the other increased
SBP. Calcium citrate ameliorates progression of kidney injury in Nx
rats,16 but we instead chose to examine Ca(HCO3)2 (CaHCO3) in an
effort to attribute the hypothesized benefit on kidney injury and
GFR preservation to HCO3. Preliminary studies showed that
NaHCO3 increased SBP over the 12-week protocol but CaHCO3
did not. MED has little added Ca2þ , but the standard rat diet
contained 221 mM g1 Ca2þ . We wanted to assure that the added
Ca2þ did not exceed the level of Ca2þ in standard diet and that
experimental and control groups received equivalent dietary HCO3.
We consequently compared animals ingesting MED with added
75 mM g1 Ca HCO3 or 150mM g
1 NaHCO3.
The fourth aim was to separate the effects of increased SBP and
amelioration of metabolic acidosis by comparing the effects of
CaHCO3 and NaHCO3 with the latter undergoing SBP reduction
with the oral antihypertensive cocktail.
The fifth aim was to rule out any possible salutary effects of the
antihypertensive cocktail independent of its effects to reduce SBP.
This was carried out by comparing the effects of added Ca2þ -
containing salts that did not increase SBP, but only one of which
decreased intrinsic acid production. These studies would help
determine if the hypothesized beneficial effects of CaHCO3 on
kidney injury and GFR preservation were due to supplemental
HCO3 that reduced intrinsic acid production or to added Ca
2þ
mediated through other mechanisms. Preliminary studies showed
that neither CaGlu nor CaHCO3 increased SBP over the 12-week
protocol. Consequently, we compared animals ingesting MED diets
with added 75 mM g1 CaGlu or 75 mM g1 CaHCO3.
The sixth aim was to determine if diets that did and did not
increase intrinsic acid production in Nx induced kidney injury and/
or led to less GFR preservation. Soy dietary protein does not
increase intrinsic acid production.4 To further test the hypothesis
that the casein effect was due to increased intrinsic acid production,
we studied animals eating 20% soy that also ingested dietary acid.
We chose (NH4)2SO4 (NH4SO4) as the dietary acid because it does
not induce distal nephron HCO3 secretion as does NH4Cl.
12 Dietary
Na2SO4 (NaSO4) (75 mM g
1) was used as a control to provide SO4
without acid.
The seventh study aim was to determine if the hypothesized
casein effects were mediated through endothelin A and/or B
receptors. MED with casein induces endothelin-dependent aug-
mented distal nephron acidification in Nx.11 Animals ingesting diets
that increased intrinsic acid production (Casein Nx and Soy
NxþNH4SO4 received bosentan (Actelion, Allschwil, Switzerland),
a nonpeptide endothelin A/B receptor antagonist,17 mixed with diet
at 100 mg kg1 body weight/day.5,6 Others received the endothelin A
receptor antagonist darusentan (Knoll, AG, Ludwigshafen/Rhein,
Germany)18 mixed with diet at 20 mg kg1 body weight/day. This
oral dose of darusentan reduces glomerulosclerosis and proteinuria
in a puromycin model of kidney injury in aging rats.19 Each
antagonist-receiving group was compared to those without
antagonist.
Eight each of Nx and sham eating MED without added salts and
without receptor antagonists were studied for the 12-week protocol.
Subsequently, eight each of Nx eating NaHCO3, NaCl, or no added
salt were studied. Eight each of these same three groups were studied
after lowering SBP with the regimen described. Eight each of two
animal groups were then studied for the 12-week protocol while
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ingesting one or the other additional salts as described. Thereafter,
eight each of the Casein Nx without added salt and Soy Nx with
added NH4SO4 were studied while ingesting bosentan, darusentan,
or none of the endothelin receptor antagonists. At 12 weeks, a 24-h
urine collection measured NAE,15 albumin excretion as a surrogate
of kidney injury,2 and urine (ET-1) excretion as a surrogate of
kidney ET-1 production.12 An arterial plasma sample was obtained
for measurement of TCO2, and animals were then anesthetized and
GFR measured as described.20
Analytical methods
Arterial plasma and urine TCO2 were measured using ultrafluoro-
metry.21 Urine albumin1 and ET-112 were measured as described
previously. Urine phosphorous was measured with the EcolineS
Phosphate kit (DiaSys, Hozheim, Germany), and urine calcium was
measured with flame atomic absorption spectrometry.
Data were expressed as means±s.e. Standard t-tests were used
for statistical comparisons for two-group comparisons and analysis
of variance was used for comparisons of more than two groups.
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